Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation

M. Kohno, M. Perch, E. Andersen, J. Carlsen, C. B. Andersen, M. Iversen

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to α1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.

Original languageEnglish
Pages (from-to)1868-1870
Number of pages3
JournalTransplantation Proceedings
Volume43
Issue number5
DOIs
Publication statusPublished - 2011 Jun

Fingerprint

Lung Transplantation
Lung Injury
Transplantation
Antilymphocyte Serum
Plasmapheresis
Interstitial Lung Diseases
Emphysema
Azathioprine
Prednisolone
Immunosuppression
Cyclosporine
Fibrosis
Therapeutics
Steroids
Inflammation
Biopsy
Lung
Health
Pharmaceutical Preparations
alemtuzumab

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. / Kohno, M.; Perch, M.; Andersen, E.; Carlsen, J.; Andersen, C. B.; Iversen, M.

In: Transplantation Proceedings, Vol. 43, No. 5, 06.2011, p. 1868-1870.

Research output: Contribution to journalArticle

Kohno, M, Perch, M, Andersen, E, Carlsen, J, Andersen, CB & Iversen, M 2011, 'Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation', Transplantation Proceedings, vol. 43, no. 5, pp. 1868-1870. https://doi.org/10.1016/j.transproceed.2011.02.007
Kohno, M. ; Perch, M. ; Andersen, E. ; Carlsen, J. ; Andersen, C. B. ; Iversen, M. / Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. In: Transplantation Proceedings. 2011 ; Vol. 43, No. 5. pp. 1868-1870.
@article{cc411af15b3d4e7eae0a43273fe63f18,
title = "Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation",
abstract = "A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to α1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.",
author = "M. Kohno and M. Perch and E. Andersen and J. Carlsen and Andersen, {C. B.} and M. Iversen",
year = "2011",
month = "6",
doi = "10.1016/j.transproceed.2011.02.007",
language = "English",
volume = "43",
pages = "1868--1870",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation

AU - Kohno, M.

AU - Perch, M.

AU - Andersen, E.

AU - Carlsen, J.

AU - Andersen, C. B.

AU - Iversen, M.

PY - 2011/6

Y1 - 2011/6

N2 - A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to α1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.

AB - A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to α1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.

UR - http://www.scopus.com/inward/record.url?scp=79959406090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959406090&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.02.007

DO - 10.1016/j.transproceed.2011.02.007

M3 - Article

VL - 43

SP - 1868

EP - 1870

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 5

ER -